Preclinical News and Research

RSS

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

For a child diagnosed with neuroblastoma-the most common infant cancer, occurring when early nerve cells grow out of control-the path to treatment isn't simple.

22 Jun 2026

Prime and pull vaccine approach prevents genital herpes infection

Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission.

22 Jun 2026

UCLA researcher receives grant for advanced osteosarcoma immunotherapy

Physician-scientist Theodore Scott Nowicki, MD, PhD, an assistant professor in the department of pediatrics hematology/oncology and microbiology, immunology, & molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded the Hero Grant from MIB Agents, a nonprofit organization dedicated to improving outcomes for children and young adults with osteosarcoma.

22 Jun 2026

Natural molecule erucamide helps slow progressive retinal degeneration

Many conditions that cause vision loss share a common feature: the gradual breakdown of the retina, the light-sensing tissue at the back of the eye.

22 Jun 2026

Tiny algae-based robots could improve bladder cancer treatment

Tiny algae-based robots guided by magnets could improve bladder cancer treatment by boosting delivery of chemotherapy drugs into tumours, researchers say.

22 Jun 2026

Copper-induced cell death stimulates antitumor immune cell responses

A preclinical study from researchers at The University of Texas MD Anderson Cancer Center, published today in Cell, details a connection between the immune system and cuproptosis, a type of copper-induced cell death.

22 Jun 2026

GATA6 loss transforms colorectal cancer cells into metastatic states

Loss of GATA6-a transcription factor that controls which genes are turned on or off-can reprogram colorectal cancer cells into more primitive, adaptable states that can then spread to the liver and establish new tumors, according to Weill Cornell Medicine and Massachusetts Institute of Technology researchers.

22 Jun 2026

Accelerating drug discovery through AI, automation, and next-generation DMTA

Discover how AI, automation, and next-generation DMTA workflows are accelerating drug discovery with expert insights from TTP leaders.

From TTP plc 19 Jun 2026

New spatial map reveals treatment vulnerabilities in bladder cancer

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder cancer, revealing how tumor cell states, immune environments and therapeutic vulnerabilities are organized within tumors.

18 Jun 2026

New mRNA vaccine shrinks neuroblastoma tumors in preclinical study

A new study from RCSI University of Medicine and Health Sciences demonstrates a novel approach in anticancer vaccine development. Results present the first preclinical evidence to show the efficacy of an mRNA vaccine in targeting neuroblastoma, the deadliest childhood cancer.

18 Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

18 Jun 2026

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Novel gene therapy appears to be safe for Friedreich ataxia cardiomyopathy

A new gene therapy appears to be safe in patients diagnosed with Friedreich ataxia cardiomyopathy, a progressive and fatal inherited cardiac disease, according to a phase 1 clinical trial led by Weill Cornell Medicine researchers.

17 Jun 2026

Engineered cartilage grafts improve surgery for narrowed child airways

A study led by researchers at Children's Hospital of Philadelphia (CHOP) demonstrated a new method of using decellularized cartilage with patient-specific cells to help enlarge the pediatric airways narrowed as a result of severe subglottic stenosis.

17 Jun 2026

New protein discovery could lead to safer antithrombotic therapies

Antiplatelet drugs are one of the main tools used to prevent thrombus formation in people who have had a heart attack or stroke or who have cardiovascular diseases with a high thrombotic risk.

17 Jun 2026

Targeting immune cells could improve colorectal cancer treatments

Researchers at the Medical University of Vienna have described a mechanism in metastatic colorectal cancer that has received little attention to date: a key target of existing therapies, the so-called epidermal growth factor receptor (EGFR), is likely to affect more than just the cancer cells themselves.

17 Jun 2026

Blood proteins reveal which aging cells may raise disease risk

...

16 Jun 2026

New study reveals cause of chronic inflammation with age

A new study led by researchers at The University of Texas MD Anderson Cancer Center has uncovered a previously unknown connection between nucleic acid structures called R-loops and age-related inflammation – or inflammaging – that could herald new intervention options for chronic inflammation and the subsequent health conditions.

16 Jun 2026

New study uncovers how prostate cancer cells evade treatment

Cancer cells are remarkably good at adapting to stress. When treatments damage them, they often find new ways to survive, fueling drug resistance and disease progression.

16 Jun 2026

Purdue develops next-generation platform to accelerate cancer drug discovery

Researchers at the Purdue Institute for Cancer Research (PICR) have developed a next-generation technology platform designed to dramatically accelerate one of the slowest and most challenging stages of cancer drug discovery: identifying promising compounds that could eventually become new therapies.

16 Jun 2026